Evolus (EOLS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 Jun, 2026Opening remarks and agenda
Meeting opened with introductions of executive management, legal counsel, and representatives from the independent auditor and election inspector.
Confirmation of proper notice to stockholders and establishment of quorum.
Meeting conducted virtually with adherence to published rules of conduct.
Shareholder proposals
Election of two class 2 directors to serve until the 2029 annual meeting.
Ratification of Ernst & Young as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory approval of named executive officer compensation.
Overview of voting outcomes
All proposals, including director elections, auditor ratification, and executive compensation, were approved by shareholders.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Evolus
- Innovative injectables portfolio delivers strong efficacy, safety, and global expansion momentum.EOLS
Scientific Investor presentation - Q2 2026 revenue up 21% to $84.1M, positive EBITDA, raised outlook, and strong global expansion.EOLS
Q2 2026 - Evolysse launch and portfolio strategy position the business for accelerated growth and market share gains.EOLS
Barclays 27th Annual Global Healthcare Conference - Shelf registration allows up to $250M in securities offerings for the cash-pay aesthetic market.EOLS
Registration filing - Diversified aesthetics portfolio, digital scale, and innovation drive growth and profitability.EOLS
Jefferies Global Healthcare Conference 2026 - Q1 2026 saw 7% revenue growth, positive Adjusted EBITDA, and reaffirmed full-year guidance.EOLS
Q1 2026 - Q3 2025 revenue up 13% to $69M, with strong Jeuveau and Evolysse growth; profitability outlook reaffirmed.EOLS
Q3 2025 - Aiming for $700M+ revenue by 2028 with new fillers, digital scale, and millennial-driven growth.EOLS
Investor Day 2024 - Record Q2 2024 revenue and first non-GAAP profit drive raised guidance and global expansion.EOLS
Q2 2024